MIT spinout Iterative Scopes has now raised $43.5m altogether from investors including Eli Lilly and Johnson & Johnson.
Iterative Scopes, a US-based precision medicine company focused on gastroenterology that is based on research at Massachusetts Institute of Technology (MIT), has completed a $30m series A round.
The round was led by Obvious Ventures, with additional commitments from pharmaceutical firms Eli Lilly and Johnson & Johnson, the latter investing through corporate venturing arm Johnson & Johnson Innovation – JJDC.
Breyer Capital, Seae Ventures and private investors also took part.
Founded in 2017, Iterative Scopes is working on artificial intelligence (AI)-powered computational tools to identify treatments and guide clinical trials for patients suffering from gastrointestinal diseases.
The series A cash has been allocated to the further development of the spinout’s core algorithms and advancing its life sciences operations.
At the same time as announcing its series A round, Iterative Scopes confirmed a total of $13.5m in seed capital raised from Wavemaker Partners, Micron Ventures, Time…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
